Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19474636 | 1.00 | MAPK1 (0.41) | MAPK1PARP1L3MBTL1KDM4EMAPT | |
| SCHEMBL14850713 | 1.00 | MAPK1 (0.41) | MAPK1PARP1L3MBTL1KDM4EMAPT | |
| SCHEMBL3995391 | 0.91 | DPP4 (0.43) | PARP1DPP4HSD17B10 | |
| SCHEMBL7341850 | 0.90 | DPP4 (0.42) | PARP1DPP4HSD17B10 | |
| SCHEMBL17596640 | 0.84 | MAPK1 (0.41) | MAPK1PARP1KDM4EMAPTTHRB | |
| SCHEMBL17596585 | 0.84 | MAPK1 (0.41) | MAPK1PARP1KDM4EMAPTTHRB | |
| SCHEMBL1343753 | 0.81 | L3MBTL1 (0.44) | MAPK1PARP1L3MBTL1KDM4EMAPT | |
| SCHEMBL15271978 | 0.81 | MAPK1 (0.39) | MAPK1PARP1L3MBTL1KDM4EMAPT | |
| SCHEMBL2674093 | 0.81 | MAPK1 (0.39) | MAPK1PARP1L3MBTL1KDM4EMAPT | |
| SCHEMBL13223548 | 0.79 | DPP4 (0.39) | L3MBTL1KDM4EDPP4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462531-A | Preparation of non-azole Process for preparing tam intermediates | 广东莱佛士制药技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-12565500-B2 | Substituted pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f][1,2,4]triazines as Btk inhibitors | BIOGEN MA INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4658262-A1 | BICYCLIC IMIDE COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4638455-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4051679-B1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| CN-119462531-A | Preparation of non-azole Process for preparing tam intermediates | 广东莱佛士制药技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462531-A | Preparation of non-azole Process for preparing tam intermediates | 广东莱佛士制药技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20140275097-A1 | NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | OGEDA SA (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2013050424-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | EUROSCREEN S.A. (BE) | 2013-04-11 | — | — | WO | disclosed |
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2307387-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | MAPK1 1458/4885PARP1 2280/4885L3MBTL1 1998/4885 |
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | MAPK1 937/4885PARP1 2653/4885L3MBTL1 4865/4885 |
| US-20140275097-A1 | NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | ACKR3, GPR3, TAC3 | MAPK1 3623/4885PARP1 1945/4885L3MBTL1 4750/4885 |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | MAPK1 1052/4885PARP1 1841/4885L3MBTL1 3686/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | MAPK1 293/4885PARP1 1629/4885L3MBTL1 3141/4885 |
| US-12565500-B2 | Substituted pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f][1,2,4]triazines as Btk inhibitors | BTK, SYK, OXSR1 | MAPK1 205/4885PARP1 662/4885L3MBTL1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.